Abstract:
3- O -Fucosyllactose is made by process which includes the hydrogenolysis of a new compound of the formula 1 wherein R 1 and R 2 are independently a group removable by hydrogenolysis, and R 3 is a group removable by hydrogenolysis or H; or a hydrate or solvate thereof.
Abstract:
The present invention provides a process for converting D-glucose into L-fucose, where a first aspect of the invention relates to a method of making a compound of formula (1) wherein R is independently H,alkyl or phenyl or, preferably, wherein the two germinal R groups together with the carbon atom to which they are attached form a C3-s cycloalkylidene group, comprising the step of treating a compound of formula (2) wherein R is defined above and R 1 is a sulphonate leaving group, with a reducing complex metal hydride and, preferably, a base to form the compound of formula (1); a compound of formula (13).
Abstract:
The invention relates to a method for making precursors of HMO core structures comprising a step of reacting an N-acetyllactosamine or lacto-N-biose derivative donor with a lactose or N-acetyllactosamine derivative acceptor, wherein the donor is an oxazoline donor.
Abstract:
The invention relates to a method for the synthesis of compounds of general formula (1A) and salts thereof wherein one of the R groups is an α-sialyl moiety and the other is H, X 1 represents a carbohydrate linker,A is a D-glucopyranosyl unit optionally substituted with fucosyl, R 1 is a protecting group that is removable by hydrogenolysis, the integer m is 0 or 1, by a transsialidation reaction.
Abstract:
The present invention relates to the isolation and purification of sialylated oligosaccharides from an aqueous medium in which they are produced.
Abstract:
This invention relates to human milk oligosaccharides (HMOs) for use in a non-infants to support better sleep quality and improve night sleep duration.
Abstract:
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS), the protein expressed being Fred.
Abstract:
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic acid encoding a protein of the MFS superfamily; and methods using said cell for the production the oligosaccharide, preferably an HMO.
Abstract:
The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non -intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2'-FL, LNnT, LNT, DFL, and 6'-SL.
Abstract:
The present invention relates to the field of recombinant production of biological molecules in host cells. The invention provides nucleic acid constructs that allow to modify expression of a desired gene using both in vitro and in vivo gene expression systems. The constructs can advantageously be used to produce a variety of biological molecules recombinantly in industrial scales, e.g. human milk oligosaccharides (HMO).